Alecensa (alectinib) / Roche 
Welcome,         Profile    Billing    Logout  
 13 Diseases   52 Trials   52 Trials   3235 News 


«12...1314151617181920212223...3637»
  • ||||||||||  YHO-1701 / Yakult Honsha
    Preclinical, Journal:  Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. (Pubmed Central) -  Oct 27, 2021   
    The combination of YHO-1701 with alectinib resulted in significantly greater antitumor activity without exhibiting body weight loss in an NCI-H2228 [echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion] xenograft mouse model. Our results strongly suggest that the logical strategy in combination with the novel STAT3 inhibitor YHO-1701 and other mechanistically different targeted agents, could be a promising approach in future clinical settings.
  • ||||||||||  Retrospective data, Review, Journal:  ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis. (Pubmed Central) -  Oct 27, 2021   
    Crizotinib for the treatment of NSCLC is associated with a higher risk for bradycardia compared to standard chemotherapy. There is no evidence of a difference in bradycardia risk between crizotinib and newer ALK inhibitors.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Alecensa (alectinib) / Roche
    Journal, Combination therapy:  Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells. (Pubmed Central) -  Oct 22, 2021   
    Although small molecule agents with RET kinase inhibitory activity such as alectinib, vandetanib, and cabozantinib have been clinically evaluated in RET-fusion-positive NSCLC, an effective monotherapy regimen has not been established...Palbociclib, a CDK4/6 inhibitor, showed the greatest synergy against LC-2/ad cells in the isobologram analysis and combination index...Another CDK4/6 inhibitor, abemaciclib, also showed a synergistic effect...This combination suppressed the phosphorylation of S6 and Rb more intensely than did either single agent in both LC-2/ad and Ba/F3-KIF5B-RET cell lines, both in vitro and in vivo. Combination therapy with alectinib plus the CDK4/6 inhibitor enhanced the antitumor effect against RET-fusion-positive cells in vitro and in vivo.
  • ||||||||||  Alecensa (alectinib) / Roche
    Preclinical, Journal:  Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin. (Pubmed Central) -  Oct 22, 2021   
    The usage of Alectinib could be another step for enhancing the effectiveness of photodynamic therapy. Further experiments will show whether photodynamic therapy in combination with Alectinib could be a new strategy for the treatment of e.g. peritoneal disseminated carcinomas.
  • ||||||||||  Alunbrig (brigatinib) / Takeda
    Trial primary completion date, Metastases:  ALTA-3: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (clinicaltrials.gov) -  Oct 22, 2021   
    P3,  N=246, Recruiting, 
    Further experiments will show whether photodynamic therapy in combination with Alectinib could be a new strategy for the treatment of e.g. peritoneal disseminated carcinomas. Trial primary completion date: Sep 2021 --> Jan 2022
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Alecensa (alectinib) / Roche
    New P2 trial:  BLISS: Brazilian Lung Immunotherapy Study (clinicaltrials.gov) -  Oct 17, 2021   
    P2,  N=154, Active, not recruiting, 
  • ||||||||||  Xalkori (crizotinib) / Pfizer
    [VIRTUAL] CRIZOTINIB-INDUCED INTERSTITIAL LUNG DISEASE () -  Oct 13, 2021 - Abstract #CHEST2021CHEST_1921;    
    It is important to consider risk factors for TKI induced ILD prior to their administration. Prompt discontinuation of the drug and treatment with corticosteroids can cause symptomatic resolution of TKI induced ILD.
  • ||||||||||  Tecentriq (atezolizumab) / Roche, Alecensa (alectinib) / Roche
    Clinical, Retrospective data, Journal:  Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: a case series. (Pubmed Central) -  Oct 10, 2021   
    Five patients presented acute abdomen symptoms and in these cases bowel perforation was the cause of death. Our experience confirms PI and perforation as rare complications of drug toxicity, especially in oncologic patients treated with combinations of different anticancer drugs and documented the second reported case of PI associated with atezolizumab and alectinib single administration.
  • ||||||||||  Alecensa (alectinib) / Roche
    Characterization of alectinib-induced hemolysis in three patients with ALK-rearranged lung cancer () -  Oct 7, 2021 - Abstract #DGHO2021DGHO_1021;    
    Genetic testing by NGS can rule out the latter whenever necessary. The differential diagnosis includes several other causes of hemolysis, especially autoimmune hemolytic anemia induced by antibiotics, cytostatic agents or immune checkpoint inhibitors, which is usually mediated by warm autoantibodies.
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
    Clinical, Journal:  Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report. (Pubmed Central) -  Oct 6, 2021   
    The differential diagnosis includes several other causes of hemolysis, especially autoimmune hemolytic anemia induced by antibiotics, cytostatic agents or immune checkpoint inhibitors, which is usually mediated by warm autoantibodies. This case suggests that alectinib, even belonging to the same drug class, could be used as an alternative agent when crizotinib is the etiology of liver damage, but more robust evidence has awaited.
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer
    Review, Journal:  A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. (Pubmed Central) -  Oct 1, 2021   
    Three-dimensional computer modeling of this double mutation and other G1202R-based double mutations with lorlatinib (ALK G1202R/L1196M, ALK G1202R/F1174C, ALK G1202R/l1198F, ALK G1202R/G1269A) were provided to reveal how these double mutations may confer resistance to lorlatinib through diverse steric hindrances in the ALK kinase domain. In addition, we performed a comprehensive literature review on published acquired double or triple ALK mutations that are resistant to lorlatinib from both patient samples and in vitro mutagenesis experiments.
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
    Retrospective data, Journal, Real-world evidence:  Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors. (Pubmed Central) -  Oct 1, 2021   
    Clinical trials have firmly established that ALK TKIs are safe, well tolerated, and effective; these findings reveal that their impact in a real-world setting is just as profound. The availability and use of ALK TKI therapies contribute to the impressive gains in survival experienced by contemporary patients with ALK-rearranged disease, rendering patients with this oncodriven form of NSCLC among the longest surviving patients with lung cancer.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Alectinib, COVID-19 and favipiravir. (Pubmed Central) -  Oct 1, 2021   
    The availability and use of ALK TKI therapies contribute to the impressive gains in survival experienced by contemporary patients with ALK-rearranged disease, rendering patients with this oncodriven form of NSCLC among the longest surviving patients with lung cancer. No abstract available
  • ||||||||||  Review, Journal:  Treatment of brain metastases in ALK-positive Non-Small Cell Lung Cancer. (Pubmed Central) -  Sep 16, 2021   
    It is therefore reasonable, in asymptomatic patients, to start treatment with specific inhibitors: RT will be used at the time of tumor progression or when symptoms appear. This sequence provides the best quality of life for patients.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Activated ALK Cooperates with N-Myc via Wnt/β-catenin Signaling to Induce Neuroendocrine Prostate Cancer. (Pubmed Central) -  Sep 15, 2021   
    We previously identified the first case of ALK F1174C-activating mutation in a patient with de novo NEPC who responded to the ALK inhibitor, alectinib...These findings point to a role for ALK signaling in NEPC and the potential of co-targeting the ALK and Wnt/β-catenin pathways in ALK-driven tumors. Activated ALK and N-Myc are well known drivers in neuroblastoma development, suggesting potential similarities and opportunities to elucidate mechanisms and therapeutic targets in NEPC and vice versa.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). (Pubmed Central) -  Sep 9, 2021   
    The reduction in tumor weight in the compound 17-treated group (10 mg/kg/day, I.V.) reached 75.82%, while alectinib reduced tumor weight by 63.82% at a dose of 20 mg/kg/day (P.O.). Taken together, our findings suggest that alectinib-based PROTACs associated with the degradation of ALK may have promising beneficial effects for treating ALK-driven malignancies.
  • ||||||||||  Clinical, Review, Journal:  Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review). (Pubmed Central) -  Sep 1, 2021   
    A series of studies have indicated that ALK‑TKI agents as the first‑line treatment, including crizotinib, ceritinib, brigatinib, alectinib and entrectinib, can benefit patients with ALK‑positive NSCLC...This study reviews the pharmacodynamics, efficacy and safety of ALK‑TKI agents in order to summarize these effects as well as the relevant management strategies. It is worth emphasizing that the frequency and severity of an adverse effect often varies across different trials.
  • ||||||||||  [VIRTUAL] Systemic therapy first (Channel 2) -  Aug 20, 2021 - Abstract #EANO2021EANO_208;    
    Particularly in HER2 positive disease, certain agents (tucatinib, neratinib and ponatinib) have shown impressive efficacy in the central nervous system. In summary, several common solid tumors with a targetable mutation and CNS metastases can be approached pharmacologically in order to avoid or delay the use of radiotherapy and it's side effects.